"","GENE","PREDICTED FUNCTION","function_freq","per_fun_freq","Drug"
"1","CYP1A2","CYP1A2 - Normal metaboliserDue to the presence of only one copy of the *1F allele, this individual is predictedto have a normal metaboliser phenotype. Normal metabolism of CYP1A2substrate drugs is predicted. Furthermore, metabolism is not expected to beincreased by exposure to inducers such as tobacco smoking and certain dietarycomponents and drugs.",69,46,"Caffeine"
"2","CYP1A2","CYP1A2 - Normal metaboliserDue to the presence of only one copy of the *1F allele, this individual is predictedto have a normal metaboliser phenotype. Normal metabolism of CYP1A2substrate drugs is predicted. Furthermore, metabolism is not expected to beincreased by exposure to inducers such as tobacco smoking and certain dietarycomponents and drugs.",69,46,"Clozapine "
"3","CYP1A2","CYP1A2 - Normal metaboliserDue to the presence of only one copy of the *1F allele, this individual is predictedto have a normal metaboliser phenotype. Normal metabolism of CYP1A2substrate drugs is predicted. Furthermore, metabolism is not expected to beincreased by exposure to inducers such as tobacco smoking and certain dietarycomponents and drugs.",69,46,"clopidogrel. "
"4","CYP1A2","CYP1A2 - Normal metaboliserDue to the presence of only one copy of the *1F allele, this individual is predictedto have a normal metaboliser phenotype. Normal metabolism of CYP1A2substrate drugs is predicted. Furthermore, metabolism is not expected to beincreased by exposure to inducers such as tobacco smoking and certain dietarycomponents and drugs.",69,46,"benzopyrene"
"5","CYP1A2","CYP1A2 - Normal metaboliserDue to the presence of only one copy of the *1F allele, this individual is predictedto have a normal metaboliser phenotype. Normal metabolism of CYP1A2substrate drugs is predicted. Furthermore, metabolism is not expected to beincreased by exposure to inducers such as tobacco smoking and certain dietarycomponents and drugs.",69,46,"aflatoxin b1"
"6","CYP1A2","CYP1A2 - Normal metaboliserThe *1F allele is not present and this individual is predicted to have a normalmetaboliser phenotype. Normal metabolism of CYP1A2 substrate drugs ispredicted. Furthermore, metabolism is not expected to be increased by exposureto inducers such as tobacco smoking and certain dietary components and drugs.",12,8,"Caffeine"
"7","CYP1A2","CYP1A2 - Normal metaboliserThe *1F allele is not present and this individual is predicted to have a normalmetaboliser phenotype. Normal metabolism of CYP1A2 substrate drugs ispredicted. Furthermore, metabolism is not expected to be increased by exposureto inducers such as tobacco smoking and certain dietary components and drugs.",12,8,"Clozapine "
"8","CYP1A2","CYP1A2 - Normal metaboliserThe *1F allele is not present and this individual is predicted to have a normalmetaboliser phenotype. Normal metabolism of CYP1A2 substrate drugs ispredicted. Furthermore, metabolism is not expected to be increased by exposureto inducers such as tobacco smoking and certain dietary components and drugs.",12,8,"clopidogrel. "
"9","CYP1A2","CYP1A2 - Normal metaboliserThe *1F allele is not present and this individual is predicted to have a normalmetaboliser phenotype. Normal metabolism of CYP1A2 substrate drugs ispredicted. Furthermore, metabolism is not expected to be increased by exposureto inducers such as tobacco smoking and certain dietary components and drugs.",12,8,"benzopyrene"
"10","CYP1A2","CYP1A2 - Normal metaboliserThe *1F allele is not present and this individual is predicted to have a normalmetaboliser phenotype. Normal metabolism of CYP1A2 substrate drugs ispredicted. Furthermore, metabolism is not expected to be increased by exposureto inducers such as tobacco smoking and certain dietary components and drugs.",12,8,"aflatoxin b1"
"11","CYP1A2","CYP1A2 - Ultrarapid metaboliser (with inducer present)Due to the presence of two *1F alleles, this individual is predicted to have anultrarapid metaboliser phenotype. Enzyme activity is highest in the presence ofinducers, such as tobacco smoke, regular consumption of cruciferous vegetablesor chargrilled meats, and certain drugs. For a drug extensively metabolised byCYP1A2, drug exposure and clinical effects may either be reduced (for an activedrug) or increased (for a prodrug).",69,46,"Caffeine"
"12","CYP1A2","CYP1A2 - Ultrarapid metaboliser (with inducer present)Due to the presence of two *1F alleles, this individual is predicted to have anultrarapid metaboliser phenotype. Enzyme activity is highest in the presence ofinducers, such as tobacco smoke, regular consumption of cruciferous vegetablesor chargrilled meats, and certain drugs. For a drug extensively metabolised byCYP1A2, drug exposure and clinical effects may either be reduced (for an activedrug) or increased (for a prodrug).",69,46,"Clozapine "
"13","CYP1A2","CYP1A2 - Ultrarapid metaboliser (with inducer present)Due to the presence of two *1F alleles, this individual is predicted to have anultrarapid metaboliser phenotype. Enzyme activity is highest in the presence ofinducers, such as tobacco smoke, regular consumption of cruciferous vegetablesor chargrilled meats, and certain drugs. For a drug extensively metabolised byCYP1A2, drug exposure and clinical effects may either be reduced (for an activedrug) or increased (for a prodrug).",69,46,"clopidogrel. "
"14","CYP1A2","CYP1A2 - Ultrarapid metaboliser (with inducer present)Due to the presence of two *1F alleles, this individual is predicted to have anultrarapid metaboliser phenotype. Enzyme activity is highest in the presence ofinducers, such as tobacco smoke, regular consumption of cruciferous vegetablesor chargrilled meats, and certain drugs. For a drug extensively metabolised byCYP1A2, drug exposure and clinical effects may either be reduced (for an activedrug) or increased (for a prodrug).",69,46,"benzopyrene"
"15","CYP1A2","CYP1A2 - Ultrarapid metaboliser (with inducer present)Due to the presence of two *1F alleles, this individual is predicted to have anultrarapid metaboliser phenotype. Enzyme activity is highest in the presence ofinducers, such as tobacco smoke, regular consumption of cruciferous vegetablesor chargrilled meats, and certain drugs. For a drug extensively metabolised byCYP1A2, drug exposure and clinical effects may either be reduced (for an activedrug) or increased (for a prodrug).",69,46,"aflatoxin b1"
"16","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"citalopram"
"17","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"clopidogrel"
"18","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"escitalopram"
"19","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"amitriptyline"
"20","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"imipramine"
"21","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"lansoprazole"
"22","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"omeprazole"
"23","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"pantoprazole"
"24","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"rabeprazole"
"25","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"sertraline"
"26","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"trimipramine"
"27","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"brivaracetam"
"28","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"voriconazole"
"29","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"clomipramine"
"30","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"dexlansoprazole"
"31","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"doxepin"
"32","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"esomeprazole"
"33","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"carisoprodol"
"34","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"clobazam"
"35","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"diazepam"
"36","CYP2C19","CYP2C19 - High intermediate metaboliserDue to the presence of one no function allele and one increased function allele,this individual is predicted to have a high intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C19, drug exposure and clinicaleffects may either be increased (for an active drug) or decreased (for a prodrug).",12,8,"flibanserin"
"37","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"citalopram"
"38","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"clopidogrel"
"39","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"escitalopram"
"40","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"amitriptyline"
"41","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"imipramine"
"42","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"lansoprazole"
"43","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"omeprazole"
"44","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"pantoprazole"
"45","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"rabeprazole"
"46","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"sertraline"
"47","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"trimipramine"
"48","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"brivaracetam"
"49","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"voriconazole"
"50","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"clomipramine"
"51","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"dexlansoprazole"
"52","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"doxepin"
"53","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"esomeprazole"
"54","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"carisoprodol"
"55","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"clobazam"
"56","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"diazepam"
"57","CYP2C19","CYP2C19 - Intermediate metaboliserDue to the presence of one normal function allele and one no function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be increased (for an active drug) or decreased (for a prodrug). Thisindividual is at risk of experiencing adverse effects (active drug) or therapeuticfailure (prodrug).",21,14,"flibanserin"
"58","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"citalopram"
"59","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"clopidogrel"
"60","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"escitalopram"
"61","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"amitriptyline"
"62","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"imipramine"
"63","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"lansoprazole"
"64","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"omeprazole"
"65","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"pantoprazole"
"66","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"rabeprazole"
"67","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"sertraline"
"68","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"trimipramine"
"69","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"brivaracetam"
"70","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"voriconazole"
"71","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"clomipramine"
"72","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"dexlansoprazole"
"73","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"doxepin"
"74","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"esomeprazole"
"75","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"carisoprodol"
"76","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"clobazam"
"77","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"diazepam"
"78","CYP2C19","CYP2C19 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C19, drug exposure and clinical effects may be expected to lie within thenormal range.",53,35.3333333333333,"flibanserin"
"79","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"citalopram"
"80","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"clopidogrel"
"81","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"escitalopram"
"82","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"amitriptyline"
"83","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"imipramine"
"84","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"lansoprazole"
"85","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"omeprazole"
"86","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"pantoprazole"
"87","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"rabeprazole"
"88","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"sertraline"
"89","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"trimipramine"
"90","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"brivaracetam"
"91","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"voriconazole"
"92","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"clomipramine"
"93","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"dexlansoprazole"
"94","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"doxepin"
"95","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"esomeprazole"
"96","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"carisoprodol"
"97","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"clobazam"
"98","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"diazepam"
"99","CYP2C19","CYP2C19 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype. For a drug extensively metabolised by CYP2C19,drug exposure and clinical effects may either be greatly increased (for an activedrug) or greatly decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",10,6.66666666666667,"flibanserin"
"100","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"citalopram"
"101","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"clopidogrel"
"102","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"escitalopram"
"103","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"amitriptyline"
"104","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"imipramine"
"105","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"lansoprazole"
"106","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"omeprazole"
"107","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"pantoprazole"
"108","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"rabeprazole"
"109","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"sertraline"
"110","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"trimipramine"
"111","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"brivaracetam"
"112","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"voriconazole"
"113","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"clomipramine"
"114","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"dexlansoprazole"
"115","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"doxepin"
"116","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"esomeprazole"
"117","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"carisoprodol"
"118","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"clobazam"
"119","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"diazepam"
"120","CYP2C19","CYP2C19 - Rapid metaboliserDue to the presence of one normal function allele and one increased functionallele, this individual is predicted to have a rapid metaboliser phenotype. For adrug extensively metabolised by CYP2C19, drug exposure and clinical effects mayeither be slightly decreased (for an active drug) or slightly increased (for aprodrug). This individual is at risk of therapeutic failure (active drug) or adverseeffects (prodrug).",50,33.3333333333333,"flibanserin"
"121","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"citalopram"
"122","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"clopidogrel"
"123","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"escitalopram"
"124","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"amitriptyline"
"125","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"imipramine"
"126","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"lansoprazole"
"127","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"omeprazole"
"128","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"pantoprazole"
"129","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"rabeprazole"
"130","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"sertraline"
"131","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"trimipramine"
"132","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"brivaracetam"
"133","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"voriconazole"
"134","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"clomipramine"
"135","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"dexlansoprazole"
"136","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"doxepin"
"137","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"esomeprazole"
"138","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"carisoprodol"
"139","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"clobazam"
"140","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"diazepam"
"141","CYP2C19","CYP2C19 - Ultrarapid metaboliserDue to the presence of two increased function alleles, this individual is predictedto have an ultrarapid metaboliser phenotype. For a drug extensively metabolisedby CYP2C19, drug exposure and clinical effects may either be decreased (for anactive drug) or increased (for a prodrug). The individual is at risk of therapeuticfailure (active drug) or adverse effects (prodrug).",4,2.66666666666667,"flibanserin"
"142","CYP2C9","CYP2C9 - High intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have a high intermediate metaboliserphenotype. For a drug extensively metabolised by CYP2C9, drug exposure andclinical effects may either be increased (for an active drug) or decreased (for aprodrug). As the *2 allele is associated with only a small reduction in enzymefunction, this variation may only be significant for certain medications, with highdosages or if drug-drug interactions occur.",23,15.3333333333333,"warfarin"
"143","CYP2C9","CYP2C9 - High intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have a high intermediate metaboliserphenotype. For a drug extensively metabolised by CYP2C9, drug exposure andclinical effects may either be increased (for an active drug) or decreased (for aprodrug). As the *2 allele is associated with only a small reduction in enzymefunction, this variation may only be significant for certain medications, with highdosages or if drug-drug interactions occur.",23,15.3333333333333,"acenocoumarol"
"144","CYP2C9","CYP2C9 - High intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have a high intermediate metaboliserphenotype. For a drug extensively metabolised by CYP2C9, drug exposure andclinical effects may either be increased (for an active drug) or decreased (for aprodrug). As the *2 allele is associated with only a small reduction in enzymefunction, this variation may only be significant for certain medications, with highdosages or if drug-drug interactions occur.",23,15.3333333333333,"celecoxib"
"145","CYP2C9","CYP2C9 - High intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have a high intermediate metaboliserphenotype. For a drug extensively metabolised by CYP2C9, drug exposure andclinical effects may either be increased (for an active drug) or decreased (for aprodrug). As the *2 allele is associated with only a small reduction in enzymefunction, this variation may only be significant for certain medications, with highdosages or if drug-drug interactions occur.",23,15.3333333333333,"flurbiprofen"
"146","CYP2C9","CYP2C9 - High intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have a high intermediate metaboliserphenotype. For a drug extensively metabolised by CYP2C9, drug exposure andclinical effects may either be increased (for an active drug) or decreased (for aprodrug). As the *2 allele is associated with only a small reduction in enzymefunction, this variation may only be significant for certain medications, with highdosages or if drug-drug interactions occur.",23,15.3333333333333,"diclofenac"
"147","CYP2C9","CYP2C9 - High intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have a high intermediate metaboliserphenotype. For a drug extensively metabolised by CYP2C9, drug exposure andclinical effects may either be increased (for an active drug) or decreased (for aprodrug). As the *2 allele is associated with only a small reduction in enzymefunction, this variation may only be significant for certain medications, with highdosages or if drug-drug interactions occur.",23,15.3333333333333,"flibanserin"
"148","CYP2C9","CYP2C9 - High intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have a high intermediate metaboliserphenotype. For a drug extensively metabolised by CYP2C9, drug exposure andclinical effects may either be increased (for an active drug) or decreased (for aprodrug). As the *2 allele is associated with only a small reduction in enzymefunction, this variation may only be significant for certain medications, with highdosages or if drug-drug interactions occur.",23,15.3333333333333,"lesinurad"
"149","CYP2C9","CYP2C9 - High intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have a high intermediate metaboliserphenotype. For a drug extensively metabolised by CYP2C9, drug exposure andclinical effects may either be increased (for an active drug) or decreased (for aprodrug). As the *2 allele is associated with only a small reduction in enzymefunction, this variation may only be significant for certain medications, with highdosages or if drug-drug interactions occur.",23,15.3333333333333,"phenytoin"
"150","CYP2C9","CYP2C9 - Intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have an intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C9, drug exposure and clinical effectsmay either be increased (for an active drug) or decreased (for a prodrug). This mayincrease the likelihood of adverse effects (active drug) or therapeutic failure(prodrug).",15,10,"warfarin"
"151","CYP2C9","CYP2C9 - Intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have an intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C9, drug exposure and clinical effectsmay either be increased (for an active drug) or decreased (for a prodrug). This mayincrease the likelihood of adverse effects (active drug) or therapeutic failure(prodrug).",15,10,"acenocoumarol"
"152","CYP2C9","CYP2C9 - Intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have an intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C9, drug exposure and clinical effectsmay either be increased (for an active drug) or decreased (for a prodrug). This mayincrease the likelihood of adverse effects (active drug) or therapeutic failure(prodrug).",15,10,"celecoxib"
"153","CYP2C9","CYP2C9 - Intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have an intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C9, drug exposure and clinical effectsmay either be increased (for an active drug) or decreased (for a prodrug). This mayincrease the likelihood of adverse effects (active drug) or therapeutic failure(prodrug).",15,10,"flurbiprofen"
"154","CYP2C9","CYP2C9 - Intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have an intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C9, drug exposure and clinical effectsmay either be increased (for an active drug) or decreased (for a prodrug). This mayincrease the likelihood of adverse effects (active drug) or therapeutic failure(prodrug).",15,10,"diclofenac"
"155","CYP2C9","CYP2C9 - Intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have an intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C9, drug exposure and clinical effectsmay either be increased (for an active drug) or decreased (for a prodrug). This mayincrease the likelihood of adverse effects (active drug) or therapeutic failure(prodrug).",15,10,"flibanserin"
"156","CYP2C9","CYP2C9 - Intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have an intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C9, drug exposure and clinical effectsmay either be increased (for an active drug) or decreased (for a prodrug). This mayincrease the likelihood of adverse effects (active drug) or therapeutic failure(prodrug).",15,10,"lesinurad"
"157","CYP2C9","CYP2C9 - Intermediate metaboliserDue to the presence of one normal function allele and one decreased functionallele, this individual is predicted to have an intermediate metaboliser phenotype.For a drug extensively metabolised by CYP2C9, drug exposure and clinical effectsmay either be increased (for an active drug) or decreased (for a prodrug). This mayincrease the likelihood of adverse effects (active drug) or therapeutic failure(prodrug).",15,10,"phenytoin"
"158","CYP2C9","CYP2C9 - Normal metaboliser",1,0.666666666666667,"warfarin"
"159","CYP2C9","CYP2C9 - Normal metaboliser",1,0.666666666666667,"acenocoumarol"
"160","CYP2C9","CYP2C9 - Normal metaboliser",1,0.666666666666667,"celecoxib"
"161","CYP2C9","CYP2C9 - Normal metaboliser",1,0.666666666666667,"flurbiprofen"
"162","CYP2C9","CYP2C9 - Normal metaboliser",1,0.666666666666667,"diclofenac"
"163","CYP2C9","CYP2C9 - Normal metaboliser",1,0.666666666666667,"flibanserin"
"164","CYP2C9","CYP2C9 - Normal metaboliser",1,0.666666666666667,"lesinurad"
"165","CYP2C9","CYP2C9 - Normal metaboliser",1,0.666666666666667,"phenytoin"
"166","CYP2C9","CYP2C9 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may be expected to lie within thenormal range.",103,68.6666666666667,"warfarin"
"167","CYP2C9","CYP2C9 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may be expected to lie within thenormal range.",103,68.6666666666667,"acenocoumarol"
"168","CYP2C9","CYP2C9 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may be expected to lie within thenormal range.",103,68.6666666666667,"celecoxib"
"169","CYP2C9","CYP2C9 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may be expected to lie within thenormal range.",103,68.6666666666667,"flurbiprofen"
"170","CYP2C9","CYP2C9 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may be expected to lie within thenormal range.",103,68.6666666666667,"diclofenac"
"171","CYP2C9","CYP2C9 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may be expected to lie within thenormal range.",103,68.6666666666667,"flibanserin"
"172","CYP2C9","CYP2C9 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may be expected to lie within thenormal range.",103,68.6666666666667,"lesinurad"
"173","CYP2C9","CYP2C9 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may be expected to lie within thenormal range.",103,68.6666666666667,"phenytoin"
"174","CYP2C9","CYP2C9 - Poor metaboliserDue to the presence of two decreased function alleles, this individual is predictedto have a poor metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may either be increased (for an activedrug) or decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug). Note that the *3allele (as opposed to the *2 allele) predicts a greater reduction in enzyme function(i.e. homozygous *3/*3 is a true poor metaboliser, whereas *2/*2 has a lesserreduction in function).",8,5.33333333333333,"warfarin"
"175","CYP2C9","CYP2C9 - Poor metaboliserDue to the presence of two decreased function alleles, this individual is predictedto have a poor metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may either be increased (for an activedrug) or decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug). Note that the *3allele (as opposed to the *2 allele) predicts a greater reduction in enzyme function(i.e. homozygous *3/*3 is a true poor metaboliser, whereas *2/*2 has a lesserreduction in function).",8,5.33333333333333,"acenocoumarol"
"176","CYP2C9","CYP2C9 - Poor metaboliserDue to the presence of two decreased function alleles, this individual is predictedto have a poor metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may either be increased (for an activedrug) or decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug). Note that the *3allele (as opposed to the *2 allele) predicts a greater reduction in enzyme function(i.e. homozygous *3/*3 is a true poor metaboliser, whereas *2/*2 has a lesserreduction in function).",8,5.33333333333333,"celecoxib"
"177","CYP2C9","CYP2C9 - Poor metaboliserDue to the presence of two decreased function alleles, this individual is predictedto have a poor metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may either be increased (for an activedrug) or decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug). Note that the *3allele (as opposed to the *2 allele) predicts a greater reduction in enzyme function(i.e. homozygous *3/*3 is a true poor metaboliser, whereas *2/*2 has a lesserreduction in function).",8,5.33333333333333,"flurbiprofen"
"178","CYP2C9","CYP2C9 - Poor metaboliserDue to the presence of two decreased function alleles, this individual is predictedto have a poor metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may either be increased (for an activedrug) or decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug). Note that the *3allele (as opposed to the *2 allele) predicts a greater reduction in enzyme function(i.e. homozygous *3/*3 is a true poor metaboliser, whereas *2/*2 has a lesserreduction in function).",8,5.33333333333333,"diclofenac"
"179","CYP2C9","CYP2C9 - Poor metaboliserDue to the presence of two decreased function alleles, this individual is predictedto have a poor metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may either be increased (for an activedrug) or decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug). Note that the *3allele (as opposed to the *2 allele) predicts a greater reduction in enzyme function(i.e. homozygous *3/*3 is a true poor metaboliser, whereas *2/*2 has a lesserreduction in function).",8,5.33333333333333,"flibanserin"
"180","CYP2C9","CYP2C9 - Poor metaboliserDue to the presence of two decreased function alleles, this individual is predictedto have a poor metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may either be increased (for an activedrug) or decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug). Note that the *3allele (as opposed to the *2 allele) predicts a greater reduction in enzyme function(i.e. homozygous *3/*3 is a true poor metaboliser, whereas *2/*2 has a lesserreduction in function).",8,5.33333333333333,"lesinurad"
"181","CYP2C9","CYP2C9 - Poor metaboliserDue to the presence of two decreased function alleles, this individual is predictedto have a poor metaboliser phenotype. For a drug extensively metabolised byCYP2C9, drug exposure and clinical effects may either be increased (for an activedrug) or decreased (for a prodrug). This individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug). Note that the *3allele (as opposed to the *2 allele) predicts a greater reduction in enzyme function(i.e. homozygous *3/*3 is a true poor metaboliser, whereas *2/*2 has a lesserreduction in function).",8,5.33333333333333,"phenytoin"
"182","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"amitriptyline"
"183","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"oxycodone"
"184","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"paroxetine"
"185","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"tamoxifen"
"186","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"tramadol"
"187","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"tropisetron"
"188","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"aripiprazole"
"189","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"brexpiprazole"
"190","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"clomipramine"
"191","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"atomoxetine"
"192","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"codeine"
"193","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"fluvoxamine"
"194","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"nortriptyline"
"195","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"ondansetron"
"196","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"methylphenidate"
"197","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"mirtazapine"
"198","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"pimozide"
"199","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"protriptyline"
"200","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"quinidine"
"201","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"risperidone"
"202","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"sertraline"
"203","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"trimipramine"
"204","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"desipramine"
"205","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"dextromethorphan"
"206","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"doxepin"
"207","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"eliglustat"
"208","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"imipramine"
"209","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"carvedilol"
"210","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"cevimeline"
"211","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"clozapine"
"212","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"darifenacin"
"213","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"dolasetron"
"214","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"duloxetine"
"215","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"fesoterodine"
"216","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"flecainide"
"217","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"venlafaxine"
"218","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"vortioxetine"
"219","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"donepezil"
"220","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"iloperidone"
"221","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"perphenazine"
"222","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"olanzapine"
"223","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"palonosetron"
"224","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"propafenone"
"225","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"propranolol"
"226","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"quinine"
"227","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"tamsulosin"
"228","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"terbinafine"
"229","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"tetrabenazine"
"230","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"flibanserin"
"231","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"fluoxetine"
"232","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"haloperidol"
"233","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"metoprolol"
"234","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"modafinil"
"235","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"galantamine"
"236","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"timolol"
"237","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"tiotropium"
"238","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"tolterodine"
"239","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"thioridazine"
"240","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one deletion and one reduced function allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",1,0.666666666666667,"zuclopenthixol"
"241","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"amitriptyline"
"242","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"oxycodone"
"243","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"paroxetine"
"244","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"tamoxifen"
"245","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"tramadol"
"246","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"tropisetron"
"247","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"aripiprazole"
"248","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"brexpiprazole"
"249","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"clomipramine"
"250","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"atomoxetine"
"251","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"codeine"
"252","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"fluvoxamine"
"253","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"nortriptyline"
"254","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"ondansetron"
"255","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"methylphenidate"
"256","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"mirtazapine"
"257","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"pimozide"
"258","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"protriptyline"
"259","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"quinidine"
"260","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"risperidone"
"261","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"sertraline"
"262","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"trimipramine"
"263","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"desipramine"
"264","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"dextromethorphan"
"265","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"doxepin"
"266","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"eliglustat"
"267","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"imipramine"
"268","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"carvedilol"
"269","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"cevimeline"
"270","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"clozapine"
"271","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"darifenacin"
"272","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"dolasetron"
"273","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"duloxetine"
"274","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"fesoterodine"
"275","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"flecainide"
"276","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"venlafaxine"
"277","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"vortioxetine"
"278","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"donepezil"
"279","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"iloperidone"
"280","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"perphenazine"
"281","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"olanzapine"
"282","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"palonosetron"
"283","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"propafenone"
"284","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"propranolol"
"285","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"quinine"
"286","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"tamsulosin"
"287","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"terbinafine"
"288","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"tetrabenazine"
"289","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"flibanserin"
"290","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"fluoxetine"
"291","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"haloperidol"
"292","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"metoprolol"
"293","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"modafinil"
"294","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"galantamine"
"295","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"timolol"
"296","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"tiotropium"
"297","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"tolterodine"
"298","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"thioridazine"
"299","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of one reduced function allele and one null allele, thisindividual is predicted to have an intermediate metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe increased (for an active drug) or decreased (for a prodrug). The individual is atrisk of experiencing adverse effects (active drug) or therapeutic failure (prodrug).",9,6,"zuclopenthixol"
"300","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"amitriptyline"
"301","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"oxycodone"
"302","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"paroxetine"
"303","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"tamoxifen"
"304","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"tramadol"
"305","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"tropisetron"
"306","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"aripiprazole"
"307","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"brexpiprazole"
"308","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"clomipramine"
"309","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"atomoxetine"
"310","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"codeine"
"311","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"fluvoxamine"
"312","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"nortriptyline"
"313","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"ondansetron"
"314","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"methylphenidate"
"315","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"mirtazapine"
"316","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"pimozide"
"317","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"protriptyline"
"318","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"quinidine"
"319","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"risperidone"
"320","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"sertraline"
"321","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"trimipramine"
"322","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"desipramine"
"323","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"dextromethorphan"
"324","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"doxepin"
"325","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"eliglustat"
"326","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"imipramine"
"327","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"carvedilol"
"328","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"cevimeline"
"329","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"clozapine"
"330","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"darifenacin"
"331","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"dolasetron"
"332","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"duloxetine"
"333","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"fesoterodine"
"334","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"flecainide"
"335","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"venlafaxine"
"336","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"vortioxetine"
"337","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"donepezil"
"338","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"iloperidone"
"339","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"perphenazine"
"340","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"olanzapine"
"341","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"palonosetron"
"342","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"propafenone"
"343","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"propranolol"
"344","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"quinine"
"345","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"tamsulosin"
"346","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"terbinafine"
"347","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"tetrabenazine"
"348","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"flibanserin"
"349","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"fluoxetine"
"350","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"haloperidol"
"351","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"metoprolol"
"352","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"modafinil"
"353","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"galantamine"
"354","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"timolol"
"355","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"tiotropium"
"356","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"tolterodine"
"357","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"thioridazine"
"358","CYP2D6","CYP2D6 - Intermediate metaboliserDue to the presence of two reduced function alleles, this individual is predicted tohave an intermediate metaboliser phenotype. For a drug extensively metabolisedby CYP2D6, drug exposure and clinical effects may either be increased (for anactive drug) or decreased (for a prodrug). The individual is at risk of experiencingadverse effects (active drug) or therapeutic failure (prodrug).",3,2,"zuclopenthixol"
"359","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"amitriptyline"
"360","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"oxycodone"
"361","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"paroxetine"
"362","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"tamoxifen"
"363","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"tramadol"
"364","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"tropisetron"
"365","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"aripiprazole"
"366","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"brexpiprazole"
"367","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"clomipramine"
"368","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"atomoxetine"
"369","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"codeine"
"370","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"fluvoxamine"
"371","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"nortriptyline"
"372","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"ondansetron"
"373","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"methylphenidate"
"374","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"mirtazapine"
"375","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"pimozide"
"376","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"protriptyline"
"377","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"quinidine"
"378","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"risperidone"
"379","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"sertraline"
"380","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"trimipramine"
"381","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"desipramine"
"382","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"dextromethorphan"
"383","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"doxepin"
"384","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"eliglustat"
"385","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"imipramine"
"386","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"carvedilol"
"387","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"cevimeline"
"388","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"clozapine"
"389","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"darifenacin"
"390","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"dolasetron"
"391","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"duloxetine"
"392","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"fesoterodine"
"393","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"flecainide"
"394","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"venlafaxine"
"395","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"vortioxetine"
"396","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"donepezil"
"397","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"iloperidone"
"398","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"perphenazine"
"399","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"olanzapine"
"400","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"palonosetron"
"401","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"propafenone"
"402","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"propranolol"
"403","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"quinine"
"404","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"tamsulosin"
"405","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"terbinafine"
"406","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"tetrabenazine"
"407","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"flibanserin"
"408","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"fluoxetine"
"409","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"haloperidol"
"410","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"metoprolol"
"411","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"modafinil"
"412","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"galantamine"
"413","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"timolol"
"414","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"tiotropium"
"415","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"tolterodine"
"416","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"thioridazine"
"417","CYP2D6","CYP2D6 - Low normal metaboliser",1,0.666666666666667,"zuclopenthixol"
"418","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"amitriptyline"
"419","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"oxycodone"
"420","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"paroxetine"
"421","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"tamoxifen"
"422","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"tramadol"
"423","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"tropisetron"
"424","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"aripiprazole"
"425","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"brexpiprazole"
"426","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"clomipramine"
"427","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"atomoxetine"
"428","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"codeine"
"429","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"fluvoxamine"
"430","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"nortriptyline"
"431","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"ondansetron"
"432","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"methylphenidate"
"433","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"mirtazapine"
"434","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"pimozide"
"435","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"protriptyline"
"436","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"quinidine"
"437","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"risperidone"
"438","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"sertraline"
"439","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"trimipramine"
"440","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"desipramine"
"441","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"dextromethorphan"
"442","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"doxepin"
"443","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"eliglustat"
"444","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"imipramine"
"445","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"carvedilol"
"446","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"cevimeline"
"447","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"clozapine"
"448","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"darifenacin"
"449","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"dolasetron"
"450","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"duloxetine"
"451","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"fesoterodine"
"452","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"flecainide"
"453","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"venlafaxine"
"454","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"vortioxetine"
"455","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"donepezil"
"456","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"iloperidone"
"457","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"perphenazine"
"458","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"olanzapine"
"459","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"palonosetron"
"460","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"propafenone"
"461","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"propranolol"
"462","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"quinine"
"463","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"tamsulosin"
"464","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"terbinafine"
"465","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"tetrabenazine"
"466","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"flibanserin"
"467","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"fluoxetine"
"468","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"haloperidol"
"469","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"metoprolol"
"470","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"modafinil"
"471","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"galantamine"
"472","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"timolol"
"473","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"tiotropium"
"474","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"tolterodine"
"475","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"thioridazine"
"476","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one deletion, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",7,4.66666666666667,"zuclopenthixol"
"477","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"amitriptyline"
"478","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"oxycodone"
"479","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"paroxetine"
"480","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"tamoxifen"
"481","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"tramadol"
"482","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"tropisetron"
"483","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"aripiprazole"
"484","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"brexpiprazole"
"485","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"clomipramine"
"486","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"atomoxetine"
"487","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"codeine"
"488","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"fluvoxamine"
"489","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"nortriptyline"
"490","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"ondansetron"
"491","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"methylphenidate"
"492","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"mirtazapine"
"493","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"pimozide"
"494","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"protriptyline"
"495","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"quinidine"
"496","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"risperidone"
"497","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"sertraline"
"498","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"trimipramine"
"499","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"desipramine"
"500","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"dextromethorphan"
"501","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"doxepin"
"502","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"eliglustat"
"503","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"imipramine"
"504","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"carvedilol"
"505","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"cevimeline"
"506","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"clozapine"
"507","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"darifenacin"
"508","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"dolasetron"
"509","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"duloxetine"
"510","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"fesoterodine"
"511","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"flecainide"
"512","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"venlafaxine"
"513","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"vortioxetine"
"514","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"donepezil"
"515","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"iloperidone"
"516","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"perphenazine"
"517","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"olanzapine"
"518","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"palonosetron"
"519","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"propafenone"
"520","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"propranolol"
"521","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"quinine"
"522","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"tamsulosin"
"523","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"terbinafine"
"524","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"tetrabenazine"
"525","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"flibanserin"
"526","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"fluoxetine"
"527","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"haloperidol"
"528","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"metoprolol"
"529","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"modafinil"
"530","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"galantamine"
"531","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"timolol"
"532","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"tiotropium"
"533","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"tolterodine"
"534","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"thioridazine"
"535","CYP2D6","CYP2D6 - Low normal metaboliserDue to the presence of one normal function allele and one null allele, thisindividual is predicted to have a low normal metaboliser phenotype. For a drugextensively metabolised by CYP2D6, drug exposure and clinical effects may eitherbe moderately above (for an active drug) or moderately below (for a prodrug) thenormal range. This genotype predicts a modest change in drug exposure which isunlikely to be clinically significant except for certain narrow therapeutic-indexdrugs, with high dosages or if drug-drug interactions occur.",33,22,"zuclopenthixol"
"536","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"amitriptyline"
"537","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"oxycodone"
"538","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"paroxetine"
"539","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"tamoxifen"
"540","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"tramadol"
"541","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"tropisetron"
"542","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"aripiprazole"
"543","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"brexpiprazole"
"544","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"clomipramine"
"545","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"atomoxetine"
"546","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"codeine"
"547","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"fluvoxamine"
"548","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"nortriptyline"
"549","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"ondansetron"
"550","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"methylphenidate"
"551","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"mirtazapine"
"552","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"pimozide"
"553","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"protriptyline"
"554","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"quinidine"
"555","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"risperidone"
"556","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"sertraline"
"557","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"trimipramine"
"558","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"desipramine"
"559","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"dextromethorphan"
"560","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"doxepin"
"561","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"eliglustat"
"562","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"imipramine"
"563","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"carvedilol"
"564","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"cevimeline"
"565","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"clozapine"
"566","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"darifenacin"
"567","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"dolasetron"
"568","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"duloxetine"
"569","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"fesoterodine"
"570","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"flecainide"
"571","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"venlafaxine"
"572","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"vortioxetine"
"573","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"donepezil"
"574","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"iloperidone"
"575","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"perphenazine"
"576","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"olanzapine"
"577","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"palonosetron"
"578","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"propafenone"
"579","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"propranolol"
"580","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"quinine"
"581","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"tamsulosin"
"582","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"terbinafine"
"583","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"tetrabenazine"
"584","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"flibanserin"
"585","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"fluoxetine"
"586","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"haloperidol"
"587","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"metoprolol"
"588","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"modafinil"
"589","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"galantamine"
"590","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"timolol"
"591","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"tiotropium"
"592","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"tolterodine"
"593","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"thioridazine"
"594","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of one normal function allele and one reduced functionallele, this individual is predicted to have a normal metaboliser phenotype. For adrug extensively metabolised by CYP2D6, drug exposure and clinical effects maybe expected to lie within the normal range.",23,15.3333333333333,"zuclopenthixol"
"595","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"amitriptyline"
"596","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"oxycodone"
"597","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"paroxetine"
"598","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"tamoxifen"
"599","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"tramadol"
"600","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"tropisetron"
"601","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"aripiprazole"
"602","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"brexpiprazole"
"603","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"clomipramine"
"604","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"atomoxetine"
"605","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"codeine"
"606","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"fluvoxamine"
"607","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"nortriptyline"
"608","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"ondansetron"
"609","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"methylphenidate"
"610","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"mirtazapine"
"611","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"pimozide"
"612","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"protriptyline"
"613","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"quinidine"
"614","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"risperidone"
"615","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"sertraline"
"616","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"trimipramine"
"617","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"desipramine"
"618","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"dextromethorphan"
"619","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"doxepin"
"620","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"eliglustat"
"621","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"imipramine"
"622","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"carvedilol"
"623","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"cevimeline"
"624","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"clozapine"
"625","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"darifenacin"
"626","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"dolasetron"
"627","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"duloxetine"
"628","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"fesoterodine"
"629","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"flecainide"
"630","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"venlafaxine"
"631","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"vortioxetine"
"632","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"donepezil"
"633","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"iloperidone"
"634","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"perphenazine"
"635","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"olanzapine"
"636","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"palonosetron"
"637","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"propafenone"
"638","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"propranolol"
"639","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"quinine"
"640","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"tamsulosin"
"641","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"terbinafine"
"642","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"tetrabenazine"
"643","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"flibanserin"
"644","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"fluoxetine"
"645","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"haloperidol"
"646","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"metoprolol"
"647","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"modafinil"
"648","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"galantamine"
"649","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"timolol"
"650","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"tiotropium"
"651","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"tolterodine"
"652","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"thioridazine"
"653","CYP2D6","CYP2D6 - Normal metaboliserDue to the presence of two normal function alleles, this individual is predicted tohave a normal metaboliser phenotype. For a drug extensively metabolised byCYP2D6, drug exposure and clinical effects may be expected to lie within thenormal range.",64,42.6666666666667,"zuclopenthixol"
"654","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"amitriptyline"
"655","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"oxycodone"
"656","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"paroxetine"
"657","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"tamoxifen"
"658","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"tramadol"
"659","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"tropisetron"
"660","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"aripiprazole"
"661","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"brexpiprazole"
"662","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"clomipramine"
"663","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"atomoxetine"
"664","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"codeine"
"665","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"fluvoxamine"
"666","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"nortriptyline"
"667","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"ondansetron"
"668","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"methylphenidate"
"669","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"mirtazapine"
"670","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"pimozide"
"671","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"protriptyline"
"672","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"quinidine"
"673","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"risperidone"
"674","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"sertraline"
"675","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"trimipramine"
"676","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"desipramine"
"677","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"dextromethorphan"
"678","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"doxepin"
"679","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"eliglustat"
"680","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"imipramine"
"681","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"carvedilol"
"682","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"cevimeline"
"683","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"clozapine"
"684","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"darifenacin"
"685","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"dolasetron"
"686","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"duloxetine"
"687","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"fesoterodine"
"688","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"flecainide"
"689","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"venlafaxine"
"690","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"vortioxetine"
"691","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"donepezil"
"692","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"iloperidone"
"693","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"perphenazine"
"694","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"olanzapine"
"695","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"palonosetron"
"696","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"propafenone"
"697","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"propranolol"
"698","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"quinine"
"699","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"tamsulosin"
"700","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"terbinafine"
"701","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"tetrabenazine"
"702","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"flibanserin"
"703","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"fluoxetine"
"704","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"haloperidol"
"705","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"metoprolol"
"706","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"modafinil"
"707","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"galantamine"
"708","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"timolol"
"709","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"tiotropium"
"710","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"tolterodine"
"711","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"thioridazine"
"712","CYP2D6","CYP2D6 - Poor metaboliserDue to the presence of two null alleles, this individual is predicted to have a poormetaboliser phenotype. For a drug extensively metabolised by CYP2D6, drugexposure and clinical effects may either be greatly increased (for an active drug) orgreatly decreased (for a prodrug). The individual is at risk of experiencing adverseeffects (active drug) or therapeutic failure (prodrug).",6,4,"zuclopenthixol"
"713","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"amitriptyline"
"714","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"oxycodone"
"715","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"paroxetine"
"716","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"tamoxifen"
"717","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"tramadol"
"718","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"tropisetron"
"719","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"aripiprazole"
"720","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"brexpiprazole"
"721","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"clomipramine"
"722","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"atomoxetine"
"723","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"codeine"
"724","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"fluvoxamine"
"725","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"nortriptyline"
"726","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"ondansetron"
"727","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"methylphenidate"
"728","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"mirtazapine"
"729","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"pimozide"
"730","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"protriptyline"
"731","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"quinidine"
"732","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"risperidone"
"733","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"sertraline"
"734","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"trimipramine"
"735","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"desipramine"
"736","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"dextromethorphan"
"737","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"doxepin"
"738","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"eliglustat"
"739","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"imipramine"
"740","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"carvedilol"
"741","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"cevimeline"
"742","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"clozapine"
"743","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"darifenacin"
"744","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"dolasetron"
"745","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"duloxetine"
"746","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"fesoterodine"
"747","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"flecainide"
"748","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"venlafaxine"
"749","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"vortioxetine"
"750","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"donepezil"
"751","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"iloperidone"
"752","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"perphenazine"
"753","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"olanzapine"
"754","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"palonosetron"
"755","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"propafenone"
"756","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"propranolol"
"757","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"quinine"
"758","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"tamsulosin"
"759","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"terbinafine"
"760","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"tetrabenazine"
"761","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"flibanserin"
"762","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"fluoxetine"
"763","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"haloperidol"
"764","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"metoprolol"
"765","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"modafinil"
"766","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"galantamine"
"767","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"timolol"
"768","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"tiotropium"
"769","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"tolterodine"
"770","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"thioridazine"
"771","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of four copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",1,0.666666666666667,"zuclopenthixol"
"772","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"amitriptyline"
"773","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"oxycodone"
"774","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"paroxetine"
"775","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"tamoxifen"
"776","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"tramadol"
"777","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"tropisetron"
"778","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"aripiprazole"
"779","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"brexpiprazole"
"780","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"clomipramine"
"781","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"atomoxetine"
"782","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"codeine"
"783","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"fluvoxamine"
"784","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"nortriptyline"
"785","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"ondansetron"
"786","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"methylphenidate"
"787","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"mirtazapine"
"788","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"pimozide"
"789","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"protriptyline"
"790","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"quinidine"
"791","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"risperidone"
"792","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"sertraline"
"793","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"trimipramine"
"794","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"desipramine"
"795","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"dextromethorphan"
"796","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"doxepin"
"797","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"eliglustat"
"798","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"imipramine"
"799","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"carvedilol"
"800","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"cevimeline"
"801","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"clozapine"
"802","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"darifenacin"
"803","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"dolasetron"
"804","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"duloxetine"
"805","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"fesoterodine"
"806","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"flecainide"
"807","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"venlafaxine"
"808","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"vortioxetine"
"809","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"donepezil"
"810","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"iloperidone"
"811","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"perphenazine"
"812","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"olanzapine"
"813","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"palonosetron"
"814","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"propafenone"
"815","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"propranolol"
"816","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"quinine"
"817","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"tamsulosin"
"818","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"terbinafine"
"819","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"tetrabenazine"
"820","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"flibanserin"
"821","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"fluoxetine"
"822","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"haloperidol"
"823","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"metoprolol"
"824","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"modafinil"
"825","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"galantamine"
"826","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"timolol"
"827","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"tiotropium"
"828","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"tolterodine"
"829","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"thioridazine"
"830","CYP2D6","CYP2D6 - Ultrarapid metaboliserDue to the presence of three copies of a normal function allele, this individual ispredicted to have an ultrarapid metaboliser phenotype. For a drug extensivelymetabolised by CYP2D6, drug exposure and clinical effects may either bedecreased (for an active drug) or increased (for a prodrug). This individual is at riskof therapeutic failure (active drug) or adverse effects (prodrug).",2,1.33333333333333,"zuclopenthixol"
"831","CYP3A4","CYP3A4 - Intermediate metaboliserThis individual carries one copy of the reduced function *22 allele and is predictedto have an intermediate metaboliser phenotype. Reduced metabolism of certainCYP3A4 substrate drugs (e.g. quetiapine) is expected. This may result in increaseddrug exposure and clinical effects.",8,5.33333333333333,"tacrolimus"
"832","CYP3A4","CYP3A4 - Normal metaboliserThe *22 allele is not present and this individual is expected to have a normalmetaboliser phenotype. Whilst many drugs are known to be metabolised byCYP3A4, relatively few genetic variations have been found that affect metabolismof a limited number of these drugs.",141,94,"tacrolimus"
"833","CYP3A5","CYP3A5 - Intermediate metaboliserThis individual carries one copy of the no function allele and is predicted to havean intermediate metaboliser phenotype (CYP3A5 expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus.",14,9.33333333333333,"tacrolimus"
"834","CYP3A5","CYP3A5 - Intermediate metaboliserThis individual carries one copy of the no function allele and is predicted to havean intermediate metaboliser phenotype (CYP3A5 expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus.",14,9.33333333333333,"atazanavir"
"835","CYP3A5","CYP3A5 - Intermediate metaboliserThis individual carries one copy of the no function allele and is predicted to havean intermediate metaboliser phenotype (CYP3A5 expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus.",14,9.33333333333333,"midazolam"
"836","CYP3A5","CYP3A5 - Intermediate metaboliserThis individual carries one copy of the no function allele and is predicted to havean intermediate metaboliser phenotype (CYP3A5 expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus.",14,9.33333333333333,"sirolimus"
"837","CYP3A5","CYP3A5 - Intermediate metaboliserThis individual carries one copy of the no function allele and is predicted to havean intermediate metaboliser phenotype (CYP3A5 expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus.",14,9.33333333333333,"cyclosporine"
"838","CYP3A5","CYP3A5 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype (CYP3A5 non-expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus. Note that this individual'sgenotype is the most common one amongst Caucasians.",136,90.6666666666667,"tacrolimus"
"839","CYP3A5","CYP3A5 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype (CYP3A5 non-expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus. Note that this individual'sgenotype is the most common one amongst Caucasians.",136,90.6666666666667,"atazanavir"
"840","CYP3A5","CYP3A5 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype (CYP3A5 non-expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus. Note that this individual'sgenotype is the most common one amongst Caucasians.",136,90.6666666666667,"midazolam"
"841","CYP3A5","CYP3A5 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype (CYP3A5 non-expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus. Note that this individual'sgenotype is the most common one amongst Caucasians.",136,90.6666666666667,"sirolimus"
"842","CYP3A5","CYP3A5 - Poor metaboliserDue to the presence of two no function alleles, this individual is predicted to havea poor metaboliser phenotype (CYP3A5 non-expresser). CYP3A5 is known tometabolise certain drugs, including tacrolimus. Note that this individual'sgenotype is the most common one amongst Caucasians.",136,90.6666666666667,"cyclosporine"
"843","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses14,15 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"alfentanil"
"844","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses14,15 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"naltrexone"
"845","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses14,15 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"tramadol"
"846","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses14,15 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"methadone"
"847","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses14,15 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"morphine"
"848","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses14,15 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"ethanol"
"849","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses14,15 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"fentanyl"
"850","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses14,15 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"naloxone"
"851","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses15,16 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",55,36.6666666666667,"alfentanil"
"852","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses15,16 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",55,36.6666666666667,"naltrexone"
"853","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses15,16 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",55,36.6666666666667,"tramadol"
"854","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses15,16 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",55,36.6666666666667,"methadone"
"855","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses15,16 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",55,36.6666666666667,"morphine"
"856","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses15,16 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",55,36.6666666666667,"ethanol"
"857","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses15,16 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",55,36.6666666666667,"fentanyl"
"858","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses15,16 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",55,36.6666666666667,"naloxone"
"859","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses16,17 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",22,14.6666666666667,"alfentanil"
"860","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses16,17 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",22,14.6666666666667,"naltrexone"
"861","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses16,17 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",22,14.6666666666667,"tramadol"
"862","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses16,17 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",22,14.6666666666667,"methadone"
"863","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses16,17 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",22,14.6666666666667,"morphine"
"864","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses16,17 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",22,14.6666666666667,"ethanol"
"865","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses16,17 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",22,14.6666666666667,"fentanyl"
"866","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses16,17 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",22,14.6666666666667,"naloxone"
"867","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses17,18 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",9,6,"alfentanil"
"868","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses17,18 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",9,6,"naltrexone"
"869","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses17,18 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",9,6,"tramadol"
"870","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses17,18 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",9,6,"methadone"
"871","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses17,18 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",9,6,"morphine"
"872","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses17,18 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",9,6,"ethanol"
"873","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses17,18 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",9,6,"fentanyl"
"874","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses17,18 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",9,6,"naloxone"
"875","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses18,19 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"alfentanil"
"876","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses18,19 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"naltrexone"
"877","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses18,19 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"tramadol"
"878","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses18,19 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"methadone"
"879","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses18,19 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"morphine"
"880","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses18,19 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"ethanol"
"881","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses18,19 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"fentanyl"
"882","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses18,19 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"naloxone"
"883","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses19,20 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",6,4,"alfentanil"
"884","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses19,20 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",6,4,"naltrexone"
"885","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses19,20 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",6,4,"tramadol"
"886","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses19,20 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",6,4,"methadone"
"887","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses19,20 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",6,4,"morphine"
"888","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses19,20 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",6,4,"ethanol"
"889","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses19,20 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",6,4,"fentanyl"
"890","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses19,20 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",6,4,"naloxone"
"891","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses20,21 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"alfentanil"
"892","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses20,21 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"naltrexone"
"893","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses20,21 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"tramadol"
"894","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses20,21 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"methadone"
"895","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses20,21 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"morphine"
"896","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses20,21 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"ethanol"
"897","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses20,21 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"fentanyl"
"898","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses20,21 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",3,2,"naloxone"
"899","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses21,22 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"alfentanil"
"900","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses21,22 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"naltrexone"
"901","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses21,22 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"tramadol"
"902","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses21,22 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"methadone"
"903","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses21,22 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"morphine"
"904","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses21,22 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"ethanol"
"905","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses21,22 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"fentanyl"
"906","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses21,22 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"naloxone"
"907","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses24,25 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"alfentanil"
"908","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses24,25 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"naltrexone"
"909","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses24,25 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"tramadol"
"910","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses24,25 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"methadone"
"911","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses24,25 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"morphine"
"912","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses24,25 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"ethanol"
"913","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses24,25 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"fentanyl"
"914","OPRM1","OPRM1 - Higher opioid sensitivityThe AA genotype contains two normal alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that this result is associated with increasedsensitivity to certain opioids (in particular, morphine) compared to those with thevariant allele (G). These findings are supported by a number of cohort studies andat least two meta-analyses24,25 however, this is not shown in all studies. Fornaltrexone in the management of alcohol use disorder, some studies have shownan association of this result with a reduced response compared to those with thevariant allele. Note the frequency of the variant allele (G) is higher in people ofAsian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"naloxone"
"915","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses15,16 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"alfentanil"
"916","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses15,16 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"naltrexone"
"917","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses15,16 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"tramadol"
"918","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses15,16 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"methadone"
"919","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses15,16 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"morphine"
"920","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses15,16 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"ethanol"
"921","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses15,16 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"fentanyl"
"922","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses15,16 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"naloxone"
"923","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses16,17 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"alfentanil"
"924","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses16,17 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"naltrexone"
"925","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses16,17 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"tramadol"
"926","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses16,17 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"methadone"
"927","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses16,17 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"morphine"
"928","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses16,17 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"ethanol"
"929","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses16,17 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"fentanyl"
"930","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses16,17 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",13,8.66666666666667,"naloxone"
"931","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses17,18 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",5,3.33333333333333,"alfentanil"
"932","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses17,18 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",5,3.33333333333333,"naltrexone"
"933","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses17,18 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",5,3.33333333333333,"tramadol"
"934","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses17,18 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",5,3.33333333333333,"methadone"
"935","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses17,18 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",5,3.33333333333333,"morphine"
"936","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses17,18 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",5,3.33333333333333,"ethanol"
"937","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses17,18 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",5,3.33333333333333,"fentanyl"
"938","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses17,18 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",5,3.33333333333333,"naloxone"
"939","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses18,19 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",2,1.33333333333333,"alfentanil"
"940","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses18,19 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",2,1.33333333333333,"naltrexone"
"941","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses18,19 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",2,1.33333333333333,"tramadol"
"942","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses18,19 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",2,1.33333333333333,"methadone"
"943","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses18,19 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",2,1.33333333333333,"morphine"
"944","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses18,19 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",2,1.33333333333333,"ethanol"
"945","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses18,19 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",2,1.33333333333333,"fentanyl"
"946","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses18,19 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",2,1.33333333333333,"naloxone"
"947","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses19,20 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"alfentanil"
"948","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses19,20 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"naltrexone"
"949","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses19,20 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"tramadol"
"950","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses19,20 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"methadone"
"951","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses19,20 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"morphine"
"952","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses19,20 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"ethanol"
"953","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses19,20 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"fentanyl"
"954","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses19,20 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"naloxone"
"955","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses24,25 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"alfentanil"
"956","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses24,25 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"naltrexone"
"957","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses24,25 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"tramadol"
"958","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses24,25 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"methadone"
"959","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses24,25 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"morphine"
"960","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses24,25 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"ethanol"
"961","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses24,25 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"fentanyl"
"962","OPRM1","OPRM1 - Intermediate opioid sensitivityThe AG genotype contains one normal allele (A) and one variant allele (G) for theOPRM1 gene which encodes the mu opioid receptor. Whilst the evidence aroundOPRM1 genetic variation continues to develop, it appears that the G allele isassociated with a reduced response to certain opioids (in particular, morphine).These findings are supported by a number of cohort studies and at least twometa-analyses24,25 however, this is not shown in all studies. For naltrexone in themanagement of alcohol use disorder, some studies have shown an association ofthe G allele with superior clinical outcomes. Note the frequency of the variantallele (G) is higher in people of Asian ancestry (around 40%) than Europeanancestry (around 15%).",1,0.666666666666667,"naloxone"
"963","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses15,16 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"alfentanil"
"964","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses15,16 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"naltrexone"
"965","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses15,16 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"tramadol"
"966","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses15,16 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"methadone"
"967","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses15,16 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"morphine"
"968","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses15,16 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"ethanol"
"969","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses15,16 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"fentanyl"
"970","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses15,16 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",4,2.66666666666667,"naloxone"
"971","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses16,17 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"alfentanil"
"972","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses16,17 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"naltrexone"
"973","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses16,17 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"tramadol"
"974","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses16,17 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"methadone"
"975","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses16,17 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"morphine"
"976","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses16,17 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"ethanol"
"977","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses16,17 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"fentanyl"
"978","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses16,17 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"naloxone"
"979","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses19,20 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",2,1.33333333333333,"alfentanil"
"980","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses19,20 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",2,1.33333333333333,"naltrexone"
"981","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses19,20 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",2,1.33333333333333,"tramadol"
"982","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses19,20 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",2,1.33333333333333,"methadone"
"983","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses19,20 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",2,1.33333333333333,"morphine"
"984","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses19,20 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",2,1.33333333333333,"ethanol"
"985","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses19,20 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",2,1.33333333333333,"fentanyl"
"986","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses19,20 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",2,1.33333333333333,"naloxone"
"987","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses24,25 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"alfentanil"
"988","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses24,25 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"naltrexone"
"989","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses24,25 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"tramadol"
"990","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses24,25 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"methadone"
"991","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses24,25 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"morphine"
"992","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses24,25 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"ethanol"
"993","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses24,25 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"fentanyl"
"994","OPRM1","OPRM1 - Lower opioid sensitivityThe GG genotype contains two variant alleles for the OPRM1 gene which encodesthe mu opioid receptor. Whilst the evidence around OPRM1 genetic variationcontinues to develop, it appears that the G allele is associated with a reducedresponse to certain opioids (in particular, morphine). These findings are supportedby a number of cohort studies and at least two meta-analyses24,25 however, this isnot shown in all studies. For naltrexone in the management of alcohol usedisorder, some studies have shown an association of the G allele with superiorclinical outcomes. Note the frequency of the variant allele (G) is higher in peopleof Asian ancestry (around 40%) than European ancestry (around 15%).",1,0.666666666666667,"naloxone"
"995","SLCO1B1","SLCO1B1 - Decreased Transporter functionThis individual carries one copy of the decreased function *5 allele and ispredicted to have decreased function of the SLCO1B1 encoded transporter.Decreased clearance of certain medications such as simvastatin is expected.",37,24.6666666666667,"simvastatin"
"996","SLCO1B1","SLCO1B1 - Decreased Transporter functionThis individual carries one copy of the decreased function *5 allele and ispredicted to have decreased function of the SLCO1B1 encoded transporter.Decreased clearance of certain medications such as simvastatin is expected.",37,24.6666666666667,"cerivastatin"
"997","SLCO1B1","SLCO1B1 - Decreased Transporter functionThis individual carries one copy of the decreased function *5 allele and ispredicted to have decreased function of the SLCO1B1 encoded transporter.Decreased clearance of certain medications such as simvastatin is expected.",37,24.6666666666667,"pravastatin"
"998","SLCO1B1","SLCO1B1 - Decreased Transporter functionThis individual carries one copy of the decreased function *5 allele and ispredicted to have decreased function of the SLCO1B1 encoded transporter.Decreased clearance of certain medications such as simvastatin is expected.",37,24.6666666666667,"rosuvastatin"
"999","SLCO1B1","SLCO1B1 - Decreased Transporter functionThis individual carries one copy of the decreased function *5 allele and ispredicted to have decreased function of the SLCO1B1 encoded transporter.Decreased clearance of certain medications such as simvastatin is expected.",37,24.6666666666667,"methotrexate"
"1000","SLCO1B1","SLCO1B1 - Normal Transporter Function",1,0.666666666666667,"simvastatin"
"1001","SLCO1B1","SLCO1B1 - Normal Transporter Function",1,0.666666666666667,"cerivastatin"
"1002","SLCO1B1","SLCO1B1 - Normal Transporter Function",1,0.666666666666667,"pravastatin"
"1003","SLCO1B1","SLCO1B1 - Normal Transporter Function",1,0.666666666666667,"rosuvastatin"
"1004","SLCO1B1","SLCO1B1 - Normal Transporter Function",1,0.666666666666667,"methotrexate"
"1005","SLCO1B1","SLCO1B1 - Normal Transporter FunctionThe decreased function *5 allele is not present and this individual is predicted tohave normal function of the SLCO1B1 encoded transporter. The transporter isimportant for the clearance of certain drugs, including simvastatin.",109,72.6666666666667,"simvastatin"
"1006","SLCO1B1","SLCO1B1 - Normal Transporter FunctionThe decreased function *5 allele is not present and this individual is predicted tohave normal function of the SLCO1B1 encoded transporter. The transporter isimportant for the clearance of certain drugs, including simvastatin.",109,72.6666666666667,"cerivastatin"
"1007","SLCO1B1","SLCO1B1 - Normal Transporter FunctionThe decreased function *5 allele is not present and this individual is predicted tohave normal function of the SLCO1B1 encoded transporter. The transporter isimportant for the clearance of certain drugs, including simvastatin.",109,72.6666666666667,"pravastatin"
"1008","SLCO1B1","SLCO1B1 - Normal Transporter FunctionThe decreased function *5 allele is not present and this individual is predicted tohave normal function of the SLCO1B1 encoded transporter. The transporter isimportant for the clearance of certain drugs, including simvastatin.",109,72.6666666666667,"rosuvastatin"
"1009","SLCO1B1","SLCO1B1 - Normal Transporter FunctionThe decreased function *5 allele is not present and this individual is predicted tohave normal function of the SLCO1B1 encoded transporter. The transporter isimportant for the clearance of certain drugs, including simvastatin.",109,72.6666666666667,"methotrexate"
"1010","SLCO1B1","SLCO1B1 - Poor Transporter FunctionDue to the presence of two decreased function alleles, this individual is predictedto have poor function of the SLCO1B1 encoded transporter. Decreased clearanceof certain medications such as simvastatin is expected.",3,2,"simvastatin"
"1011","SLCO1B1","SLCO1B1 - Poor Transporter FunctionDue to the presence of two decreased function alleles, this individual is predictedto have poor function of the SLCO1B1 encoded transporter. Decreased clearanceof certain medications such as simvastatin is expected.",3,2,"cerivastatin"
"1012","SLCO1B1","SLCO1B1 - Poor Transporter FunctionDue to the presence of two decreased function alleles, this individual is predictedto have poor function of the SLCO1B1 encoded transporter. Decreased clearanceof certain medications such as simvastatin is expected.",3,2,"pravastatin"
"1013","SLCO1B1","SLCO1B1 - Poor Transporter FunctionDue to the presence of two decreased function alleles, this individual is predictedto have poor function of the SLCO1B1 encoded transporter. Decreased clearanceof certain medications such as simvastatin is expected.",3,2,"rosuvastatin"
"1014","SLCO1B1","SLCO1B1 - Poor Transporter FunctionDue to the presence of two decreased function alleles, this individual is predictedto have poor function of the SLCO1B1 encoded transporter. Decreased clearanceof certain medications such as simvastatin is expected.",3,2,"methotrexate"
"1015","VKORC1","VKORC1 - Moderately reduced VKORC1 enzyme levelThe VKORC1 enzyme is predicted to be present in moderately reduced amountsand the response to warfarin will be enhanced. The CYP2C9 genotype should alsobe considered together with the VKORC1 genotype for calculating the initialwarfarin dose.",59,39.3333333333333,"warfarin"
"1016","VKORC1","VKORC1 - Normal VKORC1 enzyme levelThe VKORC1 enzyme is predicted to be present in normal amounts and theresponse to warfarin will be normal. The CYP2C9 genotype should also beconsidered together with the VKORC1 genotype for calculating the initial warfarindose.",57,38,"warfarin"
"1017","VKORC1","VKORC1 - Significantly reduced VKORC1 enzyme levelThe VKORC1 enzyme is predicted to be present in significantly reduced amountsand the response to warfarin will be enhanced. The CYP2C9 genotype should alsobe considered together with the VKORC1 genotype for calculating the initialwarfarin dose.",34,22.6666666666667,"warfarin"
